Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Bavarian Nordic A/S    BAVA   DK0015998017

BAVARIAN NORDIC A/S

(BAVA)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Omx Copenhagen
11/23/2020 11/24/2020 11/25/2020 11/26/2020 11/27/2020 Date
186.9(c) 181(c) 182.4(c) 185.7(c) 186.8 Last
281 042 486 598 358 641 257 396 209 971 Volume
+0.16% -3.16% +0.77% +1.81% +0.59% Change
More quotes
Financials
Sales 2020 1 973 M 317 M 317 M
Net income 2020 394 M 63,3 M 63,3 M
Net cash position 2020 972 M 156 M 156 M
P/E ratio 2020 22,6x
Yield 2020 -
Sales 2021 2 318 M 373 M 373 M
Net income 2021 153 M 24,5 M 24,5 M
Net cash position 2021 950 M 153 M 153 M
P/E ratio 2021 82,9x
Yield 2021 -
Capitalization 10 863 M 1 746 M 1 746 M
EV / Sales 2020 5,01x
EV / Sales 2021 4,28x
Nbr of Employees 649
Free-Float 98,9%
More Financials
Company
Bavarian Nordic A/S is a Denmark-based biotechnology company engaged in the development, production and marketing of vaccines for the treatment of cancer and infectious diseases. The Company’s drug pipeline comprises two areas: Cancer Immunotherapy and Infectious Disease. The Cancer Immunotherapy pipeline is focused on: prostate cancer, including PROSTVAC and Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) PRO;... 
More about the company
Notations Surperformance© of Bavarian Nordic A/S
Trading Rating : Investor Rating :
More Ratings
All news about BAVARIAN NORDIC A/S
11/19EXPRES2ION BIOTECH : announces interim results for the first nine months of 2020
AQ
11/16BAVARIAN NORDIC A/S : Report of transactions of shares and related securities of..
AQ
11/16INVESCO : Bavarian Nordic Announces Major Shareholder Notification from Invesco ..
AQ
11/16BAVARIAN NORDIC A/S : Announces Major Shareholder Notification from Invesco Ltd.
AQ
11/16ExpreS2ion announces successful manufacturing of the cVLP COVID-19 vaccine an..
AQ
11/13BAVARIAN NORDIC A/S : - Health Canada Extends Approval of IMVAMUNE to Immunizati..
AQ
11/12BAVARIAN NORDIC A/S : Health Canada Extends Approval of IMVAMUNE to Immunization..
AQ
11/12Health Canada Extends Approval of IMVAMUNE to Immunization against Monkeypox ..
GL
11/11BAVARIAN NORDIC A/S : Report of transactions of shares and related securities of..
AQ
11/11BAVARIAN NORDIC A/S : Announces Interim Results for the First Nine Months of 202..
AQ
11/11Bavarian Nordic Announces Interim Results for the First Nine Months of 2020
GL
10/12NOVO NORDISK A/S : Bavarian Nordic Announces Appointment of Anu Helena Kerns as ..
AQ
10/09BAVARIAN NORDIC A/S : Announces Appointment of Anu Helena Kerns as Executive Vic..
AQ
09/04BAVARIAN NORDIC A/S : - Transactions in Connection with Share Buy-Back Program a..
AQ
09/02BAVARIAN NORDIC A/S : – Transactions in Connection with Share Buy-Back Pro..
AQ
More news
News in other languages on BAVARIAN NORDIC A/S
11/12Les investisseurs hésitent à tout miser sur les vaccins
11/12AVIS D'ANALYSTES DU JOUR : Alcon, BMW, Delivery Hero, Getlink, Logitech, Rubis, ..
06/18Stop ou encore ?
06/18EN DIRECT DES MARCHES : PSA, FDJ, Airbus, Elis, Valneva, Nokia, Swatch, TUI, Nis..
04/09Dernière séance avant la coupure de Pâques
More news
Chart BAVARIAN NORDIC A/S
Duration : Period :
Bavarian Nordic A/S Technical Analysis Chart | BAVA | DK0015998017 | MarketScreener
Technical analysis trends BAVARIAN NORDIC A/S
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Average target price 270,71 DKK
Last Close Price 185,70 DKK
Spread / Highest target 93,9%
Spread / Average Target 45,8%
Spread / Lowest Target 15,8%
EPS Revisions
Managers
NameTitle
Paul Chaplin President & Chief Executive Officer
Gerardus Wilhelmus van Odijk Chairman
Henrik Birk Chief Operating Officer & Executive Vice President
Henrik Neilsen Juuel Chief Financial Officer & Executive Vice President
Laurence de Moerlooze Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
BAVARIAN NORDIC A/S8.31%1 733
JOHNSON & JOHNSON-1.50%378 244
ROCHE HOLDING AG-3.47%285 939
NOVARTIS AG-11.58%203 854
PFIZER INC.-1.59%203 048
MERCK & CO., INC.-11.97%202 555